Hormone-Refractory Prostate Cancer Terminated Phase 3 Trials for Custirsen (DB05487)

Also known as: Hormone Refractory Prostate Cancer Disease / Hormone Refractory Prostate Cancer / Castration-resistant prostate cancer / Hormone refractory prostate cancer (disorder)

IndicationStatusPhase
DBCOND0030169 (Hormone-Refractory Prostate Cancer)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01083615A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Treatment